Translate page

CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical papers

Scientific papers

More CML Publications 2024

Clinical Publications Scientific Publications
May 2024

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Review
Kantarjian H et al. Leukemia, May 2024

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Perusini MA et al. Blood Adv, May 2024
– open access publication

 

Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients:
Preliminary results from the DES-CML Study
Murbach B et al. Front Oncol, May 2024 – open access publication

Platelet microparticles influence gene expression and modulate biological activities of chronic myeloid leukemia cells (K562)
Nikravesh F et al. Mol Biol Rep, May 2024

Distribution of BCR::ABL1 transcripts in the different clinical phases of chronic myeloid leukemia: Effect on hematological parameter and patient survival
Romero-Morelos P et al. Genes(Basel), May 2024
– open access publication

 
April 2024
Second treatment-free remission attempt in patients with chronic myeloid leukemia – Review
Ureshino H et al. Clin Lymphoma Myeloma Leuk, April 2024
Oxidative stress and chronic myeloid leukemia: A Balance between ROS-mediated Pro- and Anti-apoptotic effects of tyrosine kinase inhibitors - Review
Allegra A et al. Antioxidants(Basel), April 2024 – open access publication
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia – Review
Özmen D et al. Expert Opin Drug Saf, April 2024
Ponatinib and STAT5 inhibitor pimozide combined synergistic treatment applications potentially overcome drug resistance via regulating the cytokine expressional network in chronic myeloid leukemia cells
Tezcanli Kaymaz B et al. J Interferon Cytokine Res, April 2024
Challenges in management of older patients with chronic myeloid leukemia – Review
Stempel JM et al. Leuk Lymphoma, April 2024 (epub ahead of print)
Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line
Demirkiran N et al. Med Oncol, April 2024
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
Nasnas PE et al. Acta Hematol, April 2024
(epub ahead of print)
Influence of genetic polyphormisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia
Cheng F et al. Int Immunopharmacol, April 2024 (epub ahead of print)
Successful pregnancy and delivery after frozen-thawed embryo transfer following the third discontinuation of tyrosine kinase inhibitor in a women with chronic myeloid leukemia
Takayama K et al. Intern Med, April 2024
(epub ahead of print)
– open access publication
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib
Leyte-Vidal A et al. Blood, April 2024
(epub ahead of print) 
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
Claudiani S et al. Leukemia, April 2024
– open access publication 
Unveiling IL6R and MYC as targeting biomarkers in imatinib-resistant CML through advanced non-invasive Apoptosis Detection Sensor Version 2 Detection
Lee CH et al. Cells, April 2024
– open access publication 

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
Onida F et al. Br J Haematol, April 2024
(epub ahead of print)
– open access publication 

Characterization of asciminib-resistant Philadelphia chromosome-positive cells
Okabe S et al. World J Oncol, April 2024
– open access publication

Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
Nesr G et al. Leuk Lymphoma, April 2024
(epub ahead of print)
– open access publication 

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
Adnan-Awad S et al. Cell Rep Med, April 2024 (epub ahead of print) 
– open access publication 
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
Curik N et al. Leukemia, April 2024 (epub ahead of print)
– open access publication 
High level of CD8+ PD-1+ cells in patients with chronic myeloid leukemia who experienced loss of MMR after imatinib discontinuation
Kwasnik P et al. Cells, April 2024
– open access publication 

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy:
a multi-institutional retrospective study by the CML Cooperative Study Group
Iriyama N et al. Int J Hematol, April 2024
(epub ahead of print) 

 
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
Jabbour E et al. Cancer, April 2024 (epub ahead of print) 
 

The Mozart effect in chronic myeloid leukemia
Stentoft J et al. Br J Haematol, April 2024
open access publication 

 
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Pérez-Lamas L et al. Ann Hematol, April 2024 (epub ahead of print)
 

Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature - Review
Sharma D et al. Ann Diagn Pathol, April 2024 (epub ahead of print) 

 
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Tian J et al. J Cancer Res Clin Oncol, April 2024 – open access publication 
 
Effect of tyrosine kinase inhibitor therapy on estimated glomerular filtration rate in patients with chronic myeloid leukemia
Sönmez Ö et al. Clin Lymphoma Myeloma Leuk, April 2024 
 
Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models
Zad Z et al. Leuk Res, April 2024
(epub ahead of print) 
 
Prognostic impact of bone marrow fibrosis and effects of tyrosine kinase inhibitors on bone marrow fibrosis in chronic myeloid leukemia
Pepeler MS et al. Clin Lymphoma Myeloma Leuk, April 2024 
 
The depth of molecular response in patients with chronic myeloid leukemia correlates with changes in humoral immunity
Janowski M et al. J Clin Med, April 2024
– open access publication
 
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase chronic myeloid leukemia
Jain AG et al. Ann Hematol, April 2024
(epub ahead of print)
– open access publication
 
March 2024
Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Chen H et al. Oncol Ther, March 2024
– open access publication
The potential of circHIPK3 as a biomarker in chronic myeloid leukemia – Review
Gomez EW et al. Front Oncol, March 2024
– open access publication
Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia
Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024
CFL1 is implicated in chronic myeloid leukemia response during imatinib therapy
Yin X et al. J Cancer, March 2024
– open access publication
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring
Omran MM et al. Eur J Clin Pharmacol, March 2024 (epub ahead of print)
 

Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts
Lee SJ et al. J Clin Lab Anal, March 2024
(epub ahead of print)
– open access publication

 
Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation
Dimitriou M et al. Blood, March 2024
– open access publication
 
Mutations in myeloid transcription factors and activated signalling genes predict chronic myeloid leukemia outcomes
Perusini MA et al. Blood Adv, March 2024
(epub ahead of print)
 
Clinical pharmacokinetics and drug-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia:
A clinical perspective – Review

Cheng F et al. Crit Rev Oncol Hematol, March 2024
 
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? – Review
Kantarjian H et al. Leukemia, March 2024
(epub ahead of print) 
 
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia positive clone or variant Philadelphia translocations
Claudiani S et al. Am J Hematol, March 2024 (epub ahead of print)
– open access publication 
 
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Brioli A et al. Leukemia, March 2024
(epub ahead of print) 
– open access publication  
 
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission
Mahon FX et al. J Clin Oncol, March 2024
(epub ahead of print) 
 
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
Smith BD et al. Leuk Res, March 2024 (epub ahead of print) 
 
High efficacy and safety of asciminib in a chronic myeloid leukemia patient with chronic kidney disease following renal transplantation
Uchida Y et al. Intern Med, March 2024 – open access publication 
 
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Bonifacio M et al. Blood Cancer J, March 2024 – open access publication 
 
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI Stopping Trial HALF
Zácková D et al. Leukemia, March 2024
(epub ahead of print) 
– open access publication 
 
The role of molecular or cytogenetic response as a favourable prognostic factor before hematopoietic cell transplantation for chronic myeloid leukemia
Medeiros GRO et al. Transplant Cell Ther, March 2024 (epub ahead of print) 
 
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia
Haddad FG et al. Am J Hematol, March 2024 (epub ahead of print)  *– open access publication 
 
The screening of microRNAs in chronic myeloid leukemia:
A clinical evaluation

Wosniaki DK et al. Int J Mol Sci, March 2024 – open access publication
 
A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia
Galimberti S et al. Pharmaceutics, March 2024 – open access publication
 
The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia
Bi X et al. J Hematol, March 2024 (epub ahead of print)
 
The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia
Nieves Saez Perdomo, M et al. Hematol Rep, March 2024
– open access publication
 
Clinical outcomes of patients with lymphoid blast phase of chronic myeloid leukemia treated with CAR T-cell therapy
Liu Y et al. Blood Cancer J, March 2024
– open access publication
 
February 2024
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANS1::ARC1A) alteration: A case report with insights on the molecular landscape
Fontana D et al. Ann Hematol, February 2024 (epub ahead of print)
Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
Jiang L et al. Genomics, February 2024
(epub ahead of print)
– open access publication
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
Wang L et al. Int J Lab Hematol, February 2024 (epub ahead of print)
Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models
Ansari AS et al. J Control Release, February 2024 (epub ahead of print)
Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction
Mu H et al. Hematol Transfus Cell Ther, February 2024
(epub ahead of print)
– open access publication
AS1041, a novel derivative of marine natural compound Aspergiolide A induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation
Lu X et al. Biomed Pharmacother, February 2024 – open access publication
HIF2-alpha expression in CML patients receiving hydroxyurea prior to imatinib that achieved major molecular response (MMR) versus in those not achieving MMR
Rinaldi I et al. J Blood Med, February 2024
(epub ahead of print)
– open access publication

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
Klaihmon P et al. Sci Rep, February 2024 (epub ahead of print)

 
Chronic myeloid leukemia 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah NP et al. J Natl Comp Canc Netw, February 2024 – open access publication 
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia - Review
El-Tanani M et al. Pathol Res Pract, February 2024 – open access publication
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis: A Report from the BCR::ABL1 Pathology Group
Rivera D et al. Mod Pathol, February 2024
– open access publication
Beyond BCR::ABL1 – The role of genomic analysis in the management of CML
Branford S et al. J Natl Comp Canc Netw, February 2024 – open access publication 
Chronic myeloid leukemia diagnosed in pregnancy: management and outcomes of 87 patients reported to the European LeukemiaNet International Registry
Chelysheva E et al. Leukemia, February 2024
(epub ahead of print)
Leukemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche
Dawson A et al. Nat Commun, February 2024
– open access publication
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
Benesova A et al. Am J Hematol, February 2024
(epub ahead of print) – open access publication
Integrated stress response potentiates ponatinib-induced cardiotoxicity
Yan G et al. Circ Res, February 2024
(epub ahead of print) 
The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: Is it the same in all settings?
Elmakaty I et al. Cancers(Basel), February 2024
– open access publication
Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: A Meta analysis
Romero-Morales P et al. Genes(Basel), February 2024
– open access publication 
Maximising the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches
Lipton JH. Clin Drug Investig, February 2024
Expression of genes potentially involved in loss of response in patients with chronic myeloid leukemia
Benegas P et al. Gene, February 2024
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myeloid leukemia patients
Alcazar V et al. Br J Haematol, February 2024
(epub ahead of print) – open access publication
State-transition modelling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
Frankhauser DE et al. Leukemia, February 2024
(epub ahead of print) – open access publication 
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: Strategies to optimize success and new directions – Review
Réa D et al. Curr Hematol Malig Rep, February 2024 (epub ahead of print)
 
Male fertility and fatherhood in chronic myeloid leukemia: Current understanding and future perspectives - Review
Elsabagh AA et al. Cancers(Basel), February 2024
– open access publication
 
Stem cell allografting for chronic myeloid leukemia in the tyrosine kinase era: Forgotten but not gone - Review
Tang K & Lipton LH. Leuk Lymphoma, February 2024 (epub ahead of print)
 
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Hornak T et al. Am J Hematol, February 2024
(epub ahead of print) – open access publication
 
Navigating the management of chronic phase chronic myeloid leukemia in the era of generic BCR::ABL1 tyrosine kinase inhibitors - Review
Haddad FG & Kantarjian H. J Natl Compr Canc Netw, February 2024 – open access publication
 
January 2024
Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A Case report and literature review
Li Y et al. Medicine (Baltimore), January 2024 – open access publication
Circ-SIRT1 upregulated ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3
Zhang R et al. Gene, January 2024
Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: A Comparative study from the Chronic Malignancies Working Party of the EBMT (CHWP-EBMT)
Ortí G et al. Transplant Cell Ther, January 2024 – open access publication
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
Sun J et al. Int J Biol Sci, January 2024
– open access publication
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Velmaat L and Cortes J. Blood, January 2024 (epub ahead of print) 
Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels
Bansal M et al. Med Oncol, January 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Jabbour E et al. Leukemia, January 2024
(epub ahead of print)
– open access publication 
Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules - Review
Bernardi S et al. Front Oncol, January 2024 – open access publication
Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches
Lipton JH. Clin Drug Investig, January 2024
(epub ahead of print) 
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation
Boucher L et al. Leuk Res, January 2024 (epub ahead of print)
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to J.P Gale and J. Chen
Pfirrmann M et al. Leukemia, January 2024
(epub ahead of print)
– open access publication 
Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia
Zhong F et al. Front Oncol, January 2024
– open access publication
Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with Dasatinib – Interim results from the DAstop2 trial
Flygt H et al. Leukemia, January 2024 (epub ahead of publication)
– open access publication 
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSC) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Benjamin ESB Cell Signal, January 2024 (epub ahead of print)
Safety and efficacy of asciminib in a chronic myloid leukemia patient with chronic kidney disease: A case report
Alshurufa A et al. Case Rep Oncol, January 2024
– open access publication 
Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia
Lettnin AP et al. Gene, January 2024
A review of the therapeutic role of bosutinib in chronic myeloid leukemia – Review
Kantarjian HM et al. Clin Lymphoma Myeloma Leuk, January 2024
Activating p53 abolishes self-renewal of quiescent leukemic stem cells in residual CML disease
Scott MT et al. Nat Commun, January 2024
– open access publication
 
Safety and efficacy of tyrosine kinase inhibitors in very elderly patients (≥ 75 years) with chronic myeloid leukemia
Costa A et al. J Clin Med, January 2024
open access publication
Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
Imeri J et al. Front Immunol, January 2024
– open access publication 
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
Dereme J et al. Ann Hematol, January 2024 (epub ahead of print)
 
What do atomic bomb survivors teach us about treatment-free remission in people with chronic myeloid leukemia
Radivoyevitch T et al. Leukemia, January 2024
– open access publication
 
How to individualized therapy after failing milestones in chronic myeloid leukemia: weighting late response and early death from CML against risk of alternative therapy
Hehlmann R and Lauseker M. Leukemia, January 2024 (epub ahead of print)
– open access publication
 
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL fusion gene in Ph-positive leukemias
Sponseiler I et al. Am J Hematol, January 2024 – open access publication
 
Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
Chen H et al. Oncol Ther, March 2024
– open access publication
 
Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia
Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024
 
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring
Omran MM et al. Eur J Clin Pharmacol, March 2024
(epub ahead of print)
 
Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts
Lee SJ et al. J Clin Lab Anal, March 2024
(epub ahead of print) – open access publication
 
Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation
Dimitriou M et al. Blood, March 2024
– open access publication
 
December 2023
CML and the WHO: Why?
Berman E et al. J Clin Oncol, December 2023 (epub ahead of print)
Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications
Ouyaung D et al. Cancers(Basel), December 2023
– open access publication
Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML
Winn AN et al. JAMA Netw Open, December 2023
open access publication
 
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis
Wu A et al. Leukemia, December 2023
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group
Rivera D et al. Mod Pathol, December 2023
(epub ahead of print)
– open access publication
The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication
Accelerated-phase CML: de novo and transformed
Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023
– open access publication 
 

A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
Zenebe B et al. Hematology Review, December 2023
– open access publication

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review
Atallah E et al. Ther Adv Hematol, December 2023
open access publication
C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells
Zehtabcheh S et al. Mol Biol Rep, December 2023

Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French
Réa D et al. Bull Cancer, December 2023
(epub ahead of print)
– open access publication 

The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia
Liu XY et al. Hematology, December 2023
– open access publication
 
Resistance mutations in CML and how we approach them - Review
Soverini S et al. Hematology Am Soc Educ Program, December 2023
– open access publication
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
Yin L et al. Hematology, December 2023
– open access publication
SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review
Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print) 
miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1
Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication
How to improve treatment-remission eligibility in CML? Review
Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication 
Osimertinib covalently binds to CD34 and eliminates progenitor cells
Xia L et al. Cancer Res, December 2023
(epub ahead of print)
The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
Liu L et al. Hematology, December 2023
– open access publication 
Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells
Yang Y et al. Hematology, December 2023
– open access publication
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019
Sasaki K et al. Cancer, December 2023
 
Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan
Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023
 
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans
Hofmann J et al. Leukemia, December 2023 – open access publication
 
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
Kongruang A et al. Hematology, December 2023
– open access publication
 
An update of the management of advanced phase chronic myeloid leukemia – Review
Short NJ et al. Curr Hematol Malig Rep, December 2023
 
Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic
Collins JB et al. J Oncol Pharm Pract, December 2023
(epub ahead of print)
– open access publication
 
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review
Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print)
 
Exploration of treatment-free remission in CML, based on molecular monitoring – Review
Zhang Z et al. Cancer Med, December 2023 (epub ahead of print)
– open access publication
 
November 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Cross NCP et al. Leukemia, November 2023
– open access publication
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen J et al. Leukemia, November 2023
(epub ahead of print)
– open access publication 
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
Zambrotta GPM et al. Am J Hematol, November 2023
– open access publication
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Shin JE et al. Mol Cancer, November 2023
– open access publication
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia:
Results from the phase 4 BYOND study

Rosti G et al. Leukemia, November 2023
(epub ahead of print)
– open access publication
Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
Häselbarth L et al. BMC Cancer, November 2023
– open access publication 
Survival with chronic myeloid leukemia after failing milestones
Lauseker M et al. Leukemia, November 2023
– open access publication
 
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
Kantarjian HM Leukemia, November 2023
 
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
Mulas O et al. Ann Hematol, November 2023
 
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
Park H et al. Ther Adv Hematol, November 2023
– open access publication

Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
Rafiq Mohammed A et al. Gene, November 2023 


October 2023
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review
Aldapt MB et al. Oncology, October 2023
(epub ahead of print)
Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review
Verhagen NE et al. Pharmaceutics, October 2023
– open access publication
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia:
a systematic review and network analysis – Review
Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)
Mitochondrial complex I inhibition by homoharringtonine:
A novel strategy for suppression of chronic myeloid leukemia

Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
Larfors G et al. Eur J Haematol, October 2023
– open access publication
A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
Zhang X et al. Cell Mol Biol Lett, October 2023
– open access publication
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
Khadadah FM et al. Leuk Res, October 2023
AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells
Lapa BS et al. Int J Mol, October 2023
– open access publication
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
Kantarjian HM et al. Lancet Haematol, October 2023
Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
Boucher L et al. Int J Mol, October 2023
– open access publication 
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
 
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
Alshurufa A et al. Case Rep Oncol, October 2023
– open access publication
 
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Efficace F et al. Cancer, October 2023
(epub ahead of print)
 

Find publications on pediatric CML here
Find publications on COVID-19 and CML here
Find CML publications from the emerging regions here

CML Publications 2014-2023

Access 2023 CML publications here

Access 2022 CML publications here

Access 2021 CML publications here

Access 2020 CML publications here

Access 2019 CML publications here

Access 2018 CML publications here

Access 2017 CML publications here

Access 2016 CML publications here

Access 2015 CML publications here

Access 2014 CML publications here


Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

Search for more publications on CML at PubMed.gov